SuperworthGENELUX price to book ratio GNLX
Market value divided by the book value of the company's net assets, since 2023.
- Today, Oct 23, 2026
- 5.6×
- 3-year median
- 5.7×
- Against its 3-year history
- 46th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 1.9× to 194×
- Peer median
- 1.6×
GENELUX's price to book ratio is 5.6× as of Oct 23, 2026.
That is below its 3-year median of 5.7×, close to the middle of its last 3 years.
Over that time it ranged from 1.9× in Aug 2024 to 194× in Jul 2023.
The median for 10 large drugmakers of a similar size is 1.6×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.6× | 4.9× | 10.8× |
| 2025 | 8.9× | 2.6× | 12.8× |
| 2024 | 2.6× | 1.9× | 15.5× |
| 2023 | 15.6× | 12.3× | 194× |
Against its peers
Companies in Drug Manufacturers - General nearest GENELUX's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| GNLXGENELUX | 5.6× |
| LFVNLifevantage | 2.2× |
| SPROSpero Therapeutics | 1.5× |
| ATNMActinium Pharmaceuticals | 1.6× |
| NATRNatures Sunshine Products | 1.3× |
| ARVNArvinas | 0.8× |
| PBYIPuma Biotechnology | 4.1× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 2.7× |
| CRMDCorMedix | 1.3× |
| COLLCollegium Pharmaceutical | 2.4× |
| Peer median | 1.6× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on GENELUX
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.